Interim safety and efficacy data to be reported in Q1VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa ...

Processa Pharmaceuticals (PCSA) reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim ...

ORLANDO, FL / ACCESS Newswire / December 26, 2025 / RedChip Companies will air interviews with Processa Pharmaceuticals, Inc.

Penny stock Processa Pharmaceuticals ($PCSA) surged as much as 130% on Wednesday. The upside is due to encouraging preliminary data from its ...

VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

Webcast Link: https://www.webcaster4.com/Webcast/Page/3023/49969 Mr. Ng will be available for one-on-one meetings throughout the conference. Investors can attend the ...

The MarketWatch News Department was not involved in the creation of this content. HANOVER, Md., June 13, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage ...

Processa Pharmaceuticals, Inc. has successfully completed a public offering, raising $5 million to support its development of next-generation chemotherapeutic drugs aimed at improving efficacy and ...

Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER, MD ...

Detailed price information for Processa Pharmaceuticals Inc (PCSA-Q) from The Globe and Mail including charting and trades.

The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on September 2, 2025. The analyst firm set a price target for $1.00 expecting PCSA to fall to ...